A carregar...
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
BACKGROUND: Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was the first agent to improve survival of patients with advanced melanoma in a rando...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2013
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4029467/ https://ncbi.nlm.nih.gov/pubmed/24423086 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-32-82 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|